Is type 2 diabetes a chronic inflammatory/autoimmune disease?

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 15, Issue 2, 2002, Pages 68-83

  Syed, M A ^a   Barinas Mitchell, E ^a   Pietropaolo, S L ^a   Zhang, Y J ^a   Henderson, T S ^a   Kelley, D E ^a   Korytkowski, M T ^a   Donahue, R P ^a   Tracy, R P ^a   Trucco, M ^a   Kuller, L H ^a   Pietropaolo, M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute phase response; Autoantibodies; Autoimmunity; Inflammation; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AUTOANTIBODY; AUTOANTIGEN; C PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INTERLEUKIN 1BETA; KETONE; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; CELL RECEPTOR; KETONE BODY; TRANSCRIPTION FACTOR;

ACUTE PHASE RESPONSE; AGE; ANIMAL CELL; ANIMAL EXPERIMENT; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BODY WEIGHT; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOMODULATION; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH; RAT; REVIEW; RISK ASSESSMENT; UNITED KINGDOM; AGING; BLOOD; CHEMISTRY; CLASSIFICATION; EDITORIAL; GENETIC POLYMORPHISM; IMMUNOLOGY; INFLAMMATION; PANCREAS ISLET; URINE;

ACUTE-PHASE REACTION; AGING; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISLETS OF LANGERHANS; KETONE BODIES; POLYMORPHISM (GENETICS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION FACTORS; DIABETES MELLITUS, TYPE 2; HUMANS; POLYMORPHISM, GENETIC;

EID: 0036109661     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey 1988-1994
2. NIDDM as a disease of the innate immune system: Association of acute phase reactants and interleukin-6 with metabolic syndrome X
3. Insulin action, diabetogenes and the cause of type II diabetes. Banting Lecture
4. New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes
5. Insulin resistance and human disease: A short history
6. Overview: What is insulin resistance?
7. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
9. Type I diabetes mellitus: A chronic autoimmune disease
10. Speculation on the etiology of diabetes mellitus. Tumbler hypothesis
11. Insulin-dependent diabetes mellitus as an autoimmune disease
12. Autoantibodies in newly diagnosed diabetic children immunoprecipitate specific human islet cell proteins
13. Autoantibodies in human diabetes
14. Pancreatic B-cell damage. In search of novel pathogenetic factors
15. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives
16. Prediction of type I diabetes mellitus in first degree relatives using a combination of insulin, glutamic acid decarboxylase and ICA512bdc/IA-2 autoantibodies
17. Aspartic acid at position 57 of the HLA-DQ beta chain protects against Type I diabetes: A family study
18. A molecular basis for MHC class II associated autoimmunity
19. Molecular basis for HLA-DQ association in IDDM
20. Diabetes Mellitus. A Fundamental and Clinical Text
21. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes
22. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus
23. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus
24. Children with obesity and diabetes; Is it type 1 or type 2?
25. The accelerator hypothesis: Weight gain as the missing link between Type I and Type II diabetes
26. Obesity and regulation of energy balance
27. Relationship between degree of obesity and in vivo insulin action in man
28. Relationship of body fat distribution to metabolic complications of obesity
29. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4
30. Diabetic ketoacidosis in obese African-Americans
31. Prevalence and clinical characteristics of type I and type II insulin-treated diabetes in the community
32. Problems related to definitions and epidemiology of type 2 (non-insulin-dependent) diabetes mellitus: Studies throughout the world
33. Can clinical characteristics predict the absence of islet cell antibodies (Abs) in black youngsters diagnosed with IDDM?
34. Medications for the treatment of diabetes
35. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
36. Type 2 diabetes mellitus in children: Pathophysiology and risk factors
37. New classification and criteria for diabetes: Moving the goalposts closer
38. Difficulties in classifying diabetes at presentation in the young adult
39. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables
40. C-peptide measurement in the differentiation of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus
41. Fasting plasma C-peptide, glucagons stimulated C-peptide, and urinary C-peptide in relation to clinical type of diabetes
42. Maturity-onset diabetes of youth in Black Americans
43. The classification of diabetes by clinical C-peptide criteria
44. Is Type II diabetes mellitus a disease of the innate immune system?
45. The instructive role of innate immunity on the acquired immune response
46. Innate immunity: Impact on the adaptive immune response
47. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes
48. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial
49. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus
50. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
51. Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons
52. High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland
53. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference interval and epidemiological applications
54. Cytokine regulation of endothelial cell function: From molecular level to the
55. Plasma levels of the soluble fraction of Tumor Necrosis Factor receptor 2 and insulin resistance
56. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology
57. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics
58. A dual role for TNF-alpha in type 1 diabetes: Islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis
59. The TNF and TNF receptor superfamilies: Integrating mammalian biology
60. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
61. The temporal importance of TN-Fα expression in the development of diabetes
62. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process
63. Noninsulin-dependent diabetes mellitus occurs in mice ectopically expressing the human ax1 tyrosine kinase receptor
64. 2 and aminoguanidine
65. Nitric oxide primes pancreatic beta cell destruction for Fas-mediated destruction in IDDM
66. Interleukin-1 effects on isolated islets: Knetics and specificity of ultrastructural changes
67. IL-1 produced and released endogenously within human islets inhibits β cell function
68. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in Type 2 diabetes
69. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha
70. The expression of TNF-alpha by human muscle: Relationship to insulin resistance
71. Elevated serum tumor necrosis factor-alpha levels contribute to the insulin resistance in type 2 (non-insulin-dependent) diabetes and in obesity
72. Circulating TNF-alpha and leptin levels in offspring of NID-DM patients do not correlate to individual insulin sensitivity
73. TNFα induced insulin resistance in vivo and its prevention by troglitazone
74. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance
75. Relationship of C-reactive proteins to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project
76. Laboratory methods and quality assurance in the Cardiovascular Health Study
77. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
78. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
79. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study
80. Subclinical disease as an independent risk factor for cardiovascular disease
81. Prospective study of serum γ-glutamyltransferase and risk of NIDDM
82. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
83. Glycaemic control and hormone replacement therapy: Implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study
84. Hormone replacement therapy, inflammation, and homeostasis in elderly women
85. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
86. The pathophysiologic roles of interleukin-6 in human disease
87. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo
88. High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians: A potential explanation for increased risk of diabetes and coronary heart disease
89. Interleukin-6 affects insulin secretion nad glucose metabolism of rat pancreatic islets in vitro
90. Interleukin 1 beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes
91. PPARγ, the ultimate thrifty gene
92. Thiazoliodinediones in the treatment of insulin resistance and type II diabetes
93. Understanding adipocyte differentiation
94. Down-regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones
95. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
96. A Pro12A1a substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
97. The common PPARgamma Pro12A1a polymorphism is associated with decreased risk of type 2 diabetes
98. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: Association with type 2 diabetes and trait differences
99. 12 →A1a substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes
100. The association between insulin resistance and endotheliopathy
101. Inflammation and coronary artery disease
102. Increased levels of soluble adhesion molecule in type 2 (non insulin-dependent) diabetes) diabetes mellitus are independent of glycaemic control
103. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: Relation to metabolic control
104. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients
105. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients
106. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities
107. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose
108. Islet cell autoantigens in insulin-dependent diabetes
109. Molecular biology of diabetes
110. Insulin-dependent diabetes mellitus
111. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies
112. Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase
113. Clinical and pathogenic significance of pancreatic-islet-cell-antibodies in diabetics treated with oral hypoglycemic agents
114. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis
115. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies
116. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes in adults with a non-insulin-dependent onset of diabetes
117. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
118. Clinical and genetic characteristics of Type 2 diabetes with and without GAD antibodies
119. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
120. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
121. + diabetes with residual β-cell function
122. Combined analysis of GAD65 and ICA512(IA-2) autoantibodies in organ and non-organ specific autoimmune disease confers high specificity for insulin-dependent diabetes mellitus
123. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies can replace the histochemical islet cell antibody test
124. Epidemiology of diabetes mellitus among the elderly in the United States
125. Current management of diabetes mellitus
126. Non-insulin-dependent diabetes mellitus in the elderly
127. Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: Correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications
128. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus
129. Diabetes in the elderly: Implications of the diabetes control and complications trial
130. Evidence of islet cell autoimmunity in elderly patients with Type 2 diabetes mellitus
131. The cardiovascular health study: Design and rationale
132. Tumor necrosis factor a and the progression of diabetes in non-obese mice
133. Islet autoantibody markers in IDDM: Risk assessment strategies yielding high sensitivity
134. GADIA2-Combi determination as first-line screening for improved prediction of type I diabetes in relatives
135. Risk assessment, prediction and prevention of type 1 diabetes
136. Are GAD65 and IA-2 autoantibodies sufficient to predict Type 1 diabetes?
137. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: The role of two HLA-DQ high-risk haplotypes
138. Absence of islet autoantibodies at diabetes onset does not rule out Type 1A diabetes
139. Diabetes prediction/prevention trials in children: Is now the time?